QUEST informs readers of the latest advances in urologic prostate cancer research, especially detection, prevention, and treatment.

Recent Findings in Prostate Cancer Research

European Study: PSA Testing Reduces Prostate Cancer Deaths Recent results from the European Randomized Study of Screening for Prostate Cancer showed that PSA-based screening lowered the risk of prostate cancer mortality by 32% for men who were 55-69 years old…

Read More
article10.1 13

Underreporting of Robotic-Assisted Surgery Complications

A study published online in the Journal for Healthcare Quality examined the reporting system for robotic-assisted surgery complications. The researchers cross-referenced reports of robotic-assisted surgery complications in legal documents and the news media with the FDA database of adverse events….

Read More
article9.1 14

The Growing Evidence Supporting Mid-life PSA Testing

Yet, due to the possible overdiagnosis and overtreatment of non-life threatening cancers, the use of routine PSA testing has become controversial. However, a recent study from Memorial Sloan-Kettering Cancer Center added to the growing body of evidence supporting the value…

Read More

Cancer Detection Tool Saves Lives

The LUGPA’s position on PSA screening is: Risks of prostate cancer screening must be uncoupled from risks of prostate cancer detection and treatment PSA testing facilitates the early detection of prostate cancer, which results in a reduced risk of being…

Read More
article7.1 12

Going the Distance

Since 1968, Chuck Koeppen has been helping students achieve their athletic goals as a cross country and track coach. His enthusiasm for coaching is evident. “It’s an incredible job,” he said. “I have a passion for the sport, but it’s…

Read More
article6.1 12

Developments in Prostate Cancer Treatment

Shorter-term Hormone Therapy For patients with high-risk prostate cancer, the current recommended duration of androgen deprivation therapy (ADT), also known as hormone therapy, is 24-36 months. However, researchers at the annual Genitourinary Cancers Symposium compared patients treated with ADT for…

Read More

Subscribe to Quest